These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 16023488)
1. Bisubstrate analog probes for the insulin receptor protein tyrosine kinase: molecular yardsticks for analyzing catalytic mechanism and inhibitor design. Hines AC; Parang K; Kohanski RA; Hubbard SR; Cole PA Bioorg Chem; 2005 Aug; 33(4):285-97. PubMed ID: 16023488 [TBL] [Abstract][Full Text] [Related]
2. Mechanism-based design of a protein kinase inhibitor. Parang K; Till JH; Ablooglu AJ; Kohanski RA; Hubbard SR; Cole PA Nat Struct Biol; 2001 Jan; 8(1):37-41. PubMed ID: 11135668 [TBL] [Abstract][Full Text] [Related]
3. ATP-conjugated peptide inhibitors for calmodulin-dependent protein kinase II. Ahn DR; Han KC; Kwon HS; Yang EG Bioorg Med Chem Lett; 2007 Jan; 17(1):147-51. PubMed ID: 17035012 [TBL] [Abstract][Full Text] [Related]
4. Protein kinase structure and function analysis with chemical tools. Shen K; Hines AC; Schwarzer D; Pickin KA; Cole PA Biochim Biophys Acta; 2005 Dec; 1754(1-2):65-78. PubMed ID: 16213197 [TBL] [Abstract][Full Text] [Related]
5. Bisubstrate inhibitors of protein kinases: from principle to practical applications. Lavogina D; Enkvist E; Uri A ChemMedChem; 2010 Jan; 5(1):23-34. PubMed ID: 19774589 [TBL] [Abstract][Full Text] [Related]
6. Computational analyses of JAK1 kinase domain: subtle changes in the catalytic cleft influence inhibitor specificity. Zhang X; Hu Y; Yuan Z Biochem Biophys Res Commun; 2008 May; 370(1):72-6. PubMed ID: 18346458 [TBL] [Abstract][Full Text] [Related]
7. Development of selective bisubstrate-based inhibitors against protein kinase C (PKC) isozymes by using dynamic peptide microarrays. Poot AJ; van Ameijde J; Slijper M; van den Berg A; Hilhorst R; Ruijtenbeek R; Rijkers DT; Liskamp RM Chembiochem; 2009 Aug; 10(12):2042-51. PubMed ID: 19618415 [TBL] [Abstract][Full Text] [Related]
8. Structural analysis of ARC-type inhibitor (ARC-1034) binding to protein kinase A catalytic subunit and rational design of bisubstrate analogue inhibitors of basophilic protein kinases. Lavogina D; Lust M; Viil I; König N; Raidaru G; Rogozina J; Enkvist E; Uri A; Bossemeyer D J Med Chem; 2009 Jan; 52(2):308-21. PubMed ID: 19143565 [TBL] [Abstract][Full Text] [Related]
9. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds. Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148 [TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and characterization of an ATP-peptide conjugate inhibitor of protein kinase A. Hines AC; Cole PA Bioorg Med Chem Lett; 2004 Jun; 14(11):2951-4. PubMed ID: 15125966 [TBL] [Abstract][Full Text] [Related]
12. Truncation and optimisation of peptide inhibitors of cyclin-dependent kinase 2-cyclin a through structure-guided design. Kontopidis G; Andrews MJ; McInnes C; Plater A; Innes L; Renachowski S; Cowan A; Fischer PM ChemMedChem; 2009 Jul; 4(7):1120-8. PubMed ID: 19472269 [TBL] [Abstract][Full Text] [Related]
13. Scaffold oriented synthesis. Part 2: Design, synthesis and biological evaluation of pyrimido-diazepines as receptor tyrosine kinase inhibitors. Gracias V; Ji Z; Akritopoulou-Zanze I; Abad-Zapatero C; Huth JR; Song D; Hajduk PJ; Johnson EF; Glaser KB; Marcotte PA; Pease L; Soni NB; Stewart KD; Davidsen SK; Michaelides MR; Djuric SW Bioorg Med Chem Lett; 2008 Apr; 18(8):2691-5. PubMed ID: 18362070 [TBL] [Abstract][Full Text] [Related]
14. Homology models of the mutated EGFR and their response towards quinazoline analogues. Kotra S; Madala KK; Jamil K J Mol Graph Model; 2008 Oct; 27(3):244-54. PubMed ID: 18585943 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of autophosphorylation of epidermal growth factor receptor by a small peptide not employing an ATP-competitive mechanism. Abe M; Kuroda Y; Hirose M; Kato M; Murakami M; Watanabe Y; Nakano M; Handa T Biopolymers; 2008 Jan; 89(1):40-51. PubMed ID: 17849478 [TBL] [Abstract][Full Text] [Related]
17. Carbocyclic 3'-deoxyadenosine-based highly potent bisubstrate-analog inhibitor of basophilic protein kinases. Enkvist E; Raidaru G; Vaasa A; Pehk T; Lavogina D; Uri A Bioorg Med Chem Lett; 2007 Oct; 17(19):5336-9. PubMed ID: 17716894 [TBL] [Abstract][Full Text] [Related]
18. In silico profiling of tyrosine kinases binding specificity and drug resistance using Monte Carlo simulations with the ensembles of protein kinase crystal structures. Verkhivker GM Biopolymers; 2007 Mar; 85(4):333-48. PubMed ID: 17167796 [TBL] [Abstract][Full Text] [Related]
19. Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4). Lafleur K; Huang D; Zhou T; Caflisch A; Nevado C J Med Chem; 2009 Oct; 52(20):6433-46. PubMed ID: 19788238 [TBL] [Abstract][Full Text] [Related]
20. The importance of CH/pi hydrogen bonds in rational drug design: An ab initio fragment molecular orbital study to leukocyte-specific protein tyrosine (LCK) kinase. Ozawa T; Tsuji E; Ozawa M; Handa C; Mukaiyama H; Nishimura T; Kobayashi S; Okazaki K Bioorg Med Chem; 2008 Dec; 16(24):10311-8. PubMed ID: 18977146 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]